What did the Mounjaro clinical trial programme actually find?

What did SURMOUNT-1 actually measure, and how big was the study?

SURMOUNT-1 was a 72-week phase 3 randomised controlled trial that enrolled 2,539 adults living with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Participants with type 2 diabetes were excluded, a separate SURMOUNT programme arm addressed that group. Everyone followed a reduced-calorie diet and increased activity alongside treatment or placebo.

At 72 weeks, average body-weight reduction was approximately 15% at the 5mg dose, rising to around 20–21% at 15mg, compared with about 3% for placebo. Some analyses placed the highest-dose figure closer to 22.5%. The results were published in the New England Journal of Medicine (SURMOUNT-1, 2022) and remain the core evidence base behind the UK licence. For a rounded view of what the SURMOUNT programme found across its different arms, our summary of tirzepatide clinical trial results covers each study in turn.

One thing worth keeping in mind: trial participants followed structured lifestyle programmes that most people outside a trial setting don't have. Real-world results vary. The trial numbers are the strongest signal we have, not a personal guarantee.

How does the dual-mechanism design explain the trial outcomes?

A question our prescribers hear most weeks is why tirzepatide seems to produce larger weight losses than older GLP-1 medicines. The answer lies in its mechanism. Tirzepatide activates two gut-hormone receptors simultaneously: GLP-1, which slows gastric emptying and signals fullness to the brain, and GIP, which also acts on appetite pathways and appears to enhance the GLP-1 effect rather than simply adding to it. The combined signal on appetite and energy regulation is meaningfully stronger than either pathway alone.

This dual-agonist profile is what distinguishes Mounjaro from Wegovy (semaglutide), which targets GLP-1 only. The full Mounjaro overview explains the mechanism in more depth, including how it differs from other medicines in this class. SURMOUNT-5 (a head-to-head randomised trial published in the New England Journal of Medicine in 2025) directly compared tirzepatide with semaglutide 2.4mg in 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. NICE's appraisal of tirzepatide (TA1026) also noted that indirect comparisons favour tirzepatide.

The NHS patient-level guidance for tirzepatide, available on the NHS tirzepatide medicines page, summarises the trial evidence alongside practical information about side effects and storage.

Who qualified for the SURMOUNT trials, and does that map onto UK eligibility?

Trial eligibility and UK licensed eligibility overlap closely but are not identical. SURMOUNT-1 enrolled adults aged 18 and over with a BMI of at least 30, or 27 with a weight-related comorbidity. The UK licence for Mounjaro follows that same shape: adults with a BMI of at least 30, or at least 27 with a qualifying condition such as prediabetes, hypertension, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

NICE's recommendation (TA1026) sets a higher bar for NHS access: BMI of at least 35 plus at least one weight-related comorbidity, with a reduction of 2.5 kg/m² for certain ethnic backgrounds. Private prescription routes follow the licensed indication rather than the NICE NHS criteria. The Eli Lilly tirzepatide trial programme overview gives context on how the broader SURPASS and SURMOUNT studies together informed the licences across diabetes and weight management indications.

BMI is a starting point, not the whole picture. A prescriber considers contraindications, current medicines, and overall health status before any decision is made. If you want to explore what the evidence means for your own situation, the weight-loss treatment options page is a practical starting point, and information about how cost compares across private providers is covered on the Mounjaro private prescription guide. If you are interested in contributing to ongoing research, our page on finding a tirzepatide clinical trial near you explains how to check whether you might be eligible to take part.

What were the key safety findings from the clinical trials?

The dominant side-effect profile across the SURMOUNT programme was gastrointestinal: nausea, vomiting, diarrhoea, constipation and indigestion were the most commonly reported, particularly after starting or increasing the dose. Most participants described these as mild to moderate, and they generally settled within days to a couple of weeks. Serious adverse events were uncommon.

Pancreatitis was identified as an infrequent but serious risk; the MHRA highlighted this in a Drug Safety Update in January 2026, advising that severe and persistent stomach pain (especially if it reaches the back) warrants urgent medical assessment. That update applies to GLP-1 medicines as a class. Trial data also showed small increases in resting heart rate, and gallbladder-related events occurred at low rates.

Treatment started at 2.5mg in all SURMOUNT arms, a tolerability dose designed to let the body adjust before the prescriber moves the dose upward, typically in four-week increments. Dosing decisions in practice stay with the prescriber and the Patient Information Leaflet, not with general reading. For a closer look at what Eli Lilly's full programme studied, the Eli Lilly tirzepatide trials page covers the SURPASS diabetes studies alongside SURMOUNT. If any of this raises questions about your own health and whether treatment might be suitable, you can also reach us through the contact page before starting a formal consultation.